Literature DB >> 6025183

Long-term follow-up of the initial (1959-1960) trachoma vaccine field trial on Taiwan.

R L Woolridge, J T Grayston, I H Chang, C Y Yang, K H Cheng.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1967        PMID： 6025183     DOI： 10.1016/0002-9394(67)94159-1

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN： 0002-9394            Impact factor:   5.258


× No keyword cloud information.
  14 in total

Review 1.  The development and use of vaccine adjuvants.

Authors:  Robert Edelman
Journal:  Mol Biotechnol       Date:  2002-06       Impact factor: 2.695

2.  The recall response induced by genital challenge with Chlamydia muridarum protects the oviduct from pathology but not from reinfection.

Authors:  Melissa M Riley; Matthew A Zurenski; Lauren C Frazer; Catherine M O'Connell; Charles W Andrews; Margaret Mintus; Toni Darville
Journal:  Infect Immun       Date:  2012-03-19       Impact factor: 3.441

3.  Identification of Chlamydia trachomatis Antigens Recognized by T Cells From Highly Exposed Women Who Limit or Resist Genital Tract Infection.

Authors:  Ali N Russell; Xiaojing Zheng; Catherine M O'Connell; Harold C Wiesenfeld; Sharon L Hillier; Brandie D Taylor; Michelle D Picard; Jessica B Flechtner; Wujuan Zhong; Lauren C Frazer; Toni Darville
Journal:  J Infect Dis       Date:  2016-10-12       Impact factor: 5.226

4.  Chlamydia trachomatis genital tract infection of antibody-deficient gene knockout mice.

Authors:  H Su; K Feilzer; H D Caldwell; R P Morrison
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

5.  Prior genital tract infection with a murine or human biovar of Chlamydia trachomatis protects mice against heterotypic challenge infection.

Authors:  K H Ramsey; T W Cotter; R D Salyer; G S Miranpuri; M A Yanez; C E Poulsen; J L DeWolfe; G I Byrne
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

6.  Disease outcome subsequent to primary and secondary urogenital infection with murine or human biovars of Chlamydia trachomatis.

Authors:  K H Ramsey; J L DeWolfe; R D Salyer
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

7.  Fc receptor regulation of protective immunity against Chlamydia trachomatis.

Authors:  Terri Moore; Godwin A Ananaba; Jacqueline Bolier; Samera Bowers; Tesfaye Belay; Francis O Eko; Joseph U Igietseme
Journal:  Immunology       Date:  2002-02       Impact factor: 7.397

8.  The natural history of trachoma infection and disease in a Gambian cohort with frequent follow-up.

Authors:  Nicholas C Grassly; Michael E Ward; Shirley Ferris; David C Mabey; Robin L Bailey
Journal:  PLoS Negl Trop Dis       Date:  2008-12-02

Review 9.  Future of human Chlamydia vaccine: potential of self-adjuvanting biodegradable nanoparticles as safe vaccine delivery vehicles.

Authors:  Rajnish Sahu; Richa Verma; Saurabh Dixit; Joseph U Igietseme; Carolyn M Black; Skyla Duncan; Shree R Singh; Vida A Dennis
Journal:  Expert Rev Vaccines       Date:  2018-02-06       Impact factor: 5.217

10.  Blockade of epithelial membrane protein 2 (EMP2) abrogates infection of Chlamydia muridarum murine genital infection model.

Authors:  Kaori Shimazaki; Ann M Chan; Raymond J Moniz; Madhuri Wadehra; Agnes Nagy; Catherine P Coulam; Sergey Mareninov; Eric M Lepin; Anna M Wu; Kathleen A Kelly; Jonathan Braun; Lynn K Gordon
Journal:  FEMS Immunol Med Microbiol       Date:  2009-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.